Billionaire Louis Bacon’s 10 Stock Picks with Huge Upside Potential

Published December 5, 2023 at 11:01 am EST Updated September 7, 2026 at 12:11 pm EDT

In this article, we discuss billionaire Louis Bacon’s 10 stock picks with huge upside potential.

Louis Bacon is a macro-trading legend on Wall Street. Macro traders capitalize on financial markets through examination of economic indicators like GDP growth, inflation rates, and unemployment data to make strategic investment decisions. Mr. Bacon founded his investment management firm Moore Capital Management in 1989 with $25,000, and before closing his hedge fund in 2019, the firm had average annualized returns of 17.6% since its inception.

While Louis Bacon is one of the most respected investors, he has had his fair share of failures at the beginning of his investing career and learned from them. He received his Bachelor of Arts degree in American literature in 1979 from Middlebury College in Vermont and worked as a clerk at Walter N. Frank & Co. while he was completing his MBA from Columbia Business School. Bacon’s initial investments involved trading commodities, and he lost on sugar, cotton, and gold contracts three times in a row. He had to ask his father for help and started seeing success after his fourth attempt.

Some of Louis Bacon’s most successful trades include predicting the 1987 market crash, shorting the S&P futures, and later, taking long positions when the market hit its bottom. In 1989, shortly after establishing his hedge fund, he shorted the Japanese Nikkei index and returned 86% due to the Japanese market crash. Finally, he also predicted Iraq’s invasion of Kuwait and made big money on oil. By 2019, his flagship, Remington funds, made a cumulative return of over 21,000%.

He closed his fund to outside investors in 2019 mentioning poor performance in the prior couple of years. He said in a letter:

“Dear Investor, As Moore Capital Management (MCM) approaches its 30th year at the end of this decade, the time is propitious to take a step I have eyed for some time and “privatize” our three multi manager flagship funds– that is to say returning client assets and funding the multi-manager program with private capital from the principals at MCM. These three funds –MGI (Moore Global Investments), RIS (Remington Investment Strategies) and MMM (Moore Macro Advisors)–will (post the return of investor funds) be consolidated into one proprietary fund which will continue to trade and invest with the same line-up of Portfolio Managers, but with less participation from me. Although this has not been an easy decision given the loyalty of Moore’s macro investors over the decades to whom I am forever grateful, it will allow me the space to step away for significant periods of time when my other interests abound without the ongoing weight and responsibility of looking after public investors’ capital on a continual basis. Disappointing results of these funds of the last few years obviously inform this decision but our long term record is one we remain proud of having delivered a net annualized return of 17.6% and a cumulative return of over 21,000% since inception for our original flagship Remington funds; annualized return of 15% for MGI and a cumulative return of 61 times original investors capital. MMM has returned 11% over its shorter lifespan. All three of the funds have returned low single digits year to date in 2019. Intense competition for trading talent coupled with client pressure on fees has led to a challenging business model for multi manager funds such as ours.”

Louis Bacon’s Q3 Bets

Despite stepping down as a hedge fund manager, Louis Bacon still has an investment portfolio. His top picks with huge upside potential include NVIDIA Corporation (NASDAQ:NVDA), Meta Platforms, Inc. (NASDAQ:META), and CRH plc (NYSE:CRH). The legendary investor is also involved in options trading and has leveraged Call options on iShares 7-10 Year Treasury Bond ETF and Materials Select Sector SPDR Fund. Additionally, Mr. Bacon seems to be keeping a bearish sentiment on the market and has placed Put options against SPDR S&P 500 ETF Trust. He also placed nearly $27 million worth of bets against Tesla, Inc. (NASDAQ:TSLA) in Q3.

In the third quarter, Louis Bacon’s 13F portfolio was worth $5.36 billion, compared to $5.81 billion in the previous quarter. Bacon made several changes to his portfolio over the quarter, including making over 170 new purchases and closing out of 193 stocks. Some of his notable purchases include Thermo Fisher Scientific Inc. (NYSE:TMO), The Procter & Gamble Company (NYSE:PG), and American Tower Corporation (NYSE:AMT). Bacon’s top three stocks in the third quarter were NVIDIA Corporation, Meta Platforms, Inc., and Alphabet Inc. (NASDAQ:GOOGL). He increased his holdings in Class A shares of Alphabet Inc. by 4,105% and initiated a position in Class C shares of Alphabet Inc. (NASDAQ:GOOG).

To check out the stocks with huge upside potential in other billionaire portfolios, you can go to Billionaire Lee Cooperman’s 10 Stock Picks with Huge Upside Potential and Billionaire Gabelli’s 10 Stock Picks with Huge Upside Potential.

Billionaire Louis Bacon's 10 Stock Picks with Huge Upside Potential

Our Methodology

For this article, we checked the average analyst price target and upside of the top 50 holdings (excluding ETFs and options) in Louis Bacon’s Q3 2023 13F portfolio. We selected the 10 stocks with the highest average analyst price target upside as of December 4 and listed the stocks in ascending order of Bacon’s stake value.

We took the average analyst price target of each stock from TipRanks.

Billionaire Louis Bacon’s 10 Stock Picks with Huge Upside Potential

10. Biogen Inc. (NASDAQ:BIIB)

Louis Bacon’s Stake Value: $384.312 million

Average analyst price target: $316.29

Average analyst price target upside: 35.83%

Biogen Inc. (NASDAQ:BIIB) is a Massachusetts-based biotech company that works on treatments for numerous neurological and neurodegenerative diseases from discovery to distribution.

On November 9, BMO Capital decreased the price target on Biogen Inc.’s stock to $295 from $314 while keeping an Outperform rating. The analyst mentioned Leqembi’s potential over the long term and approval of Skyclaris in the E.U. as potential tailwinds.

On November 8, Biogen Inc. reported its Q3 earnings result with a non-GAAP EPS of $4.36, topping the analysts’ estimates by $0.37. The revenue grew 0.8% year-over-year (YoY) to $2.53 billion, which beat the estimates by $130 million.

Biogen Inc. is one of Louis Bacon’s top stock picks with huge upside potential, along with NVIDIA Corporation, Meta Platforms, Inc., and CRH plc (NYSE:CRH).

9. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Louis Bacon’s Stake Value: $17.27 million

Average analyst price target: $110.15

Average analyst price target upside: 16.68%

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a California-based biotechnology company that discovers and commercializes medicines in clinical and preclinical stages for rare genetic disorders.

BioMarin Pharmaceutical Inc.’s stock has been covered by 23 Wall Street analysts over the last three months, and 15 keep a Buy rating on the shares. The average price target shows an upside of 16.68% as of December 4.

On November 15, Wells Fargo started coverage of BioMarin Pharmaceutical Inc.’s stock with a price target of $100 and an Overweight rating. The firm expects significant growth for the company in the next four to five years.

Aristotle Atlantic Partners, LLC mentioned BioMarin Pharmaceutical Inc. in its first quarter 2023 investor letter. Here is what it said:

“BioMarin Pharmaceutical Inc. develops drugs with a focus on rare disease treatments. Its portfolio consists of several commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. The company’s Vimizim, Naglazyme and Aldurazyme drugs treat versions of the life-threatening genetic condition mucopolysaccharidosis (MPS), caused by a rare enzyme deficiency that prevents patients from metabolizing certain complex carbohydrates. Another drug, Kuvan, is approved to treat enzyme deficiency phenylketonuria (PKU). Additional medicines include Brineura and Palynziq.

We see BioMarin, anchored by their durable enzyme-based therapies, poised to grow from new indications, primarily Voxzogo, the first-approved treatment for Achondroplasia, and Roctavian, a drug awaiting FDA approval for the treatment of Severe Hemophilia A, with gene therapy and the ability to address a large chronically managed patient population. Additionally, the company has an early pipeline outside of these major indications in rare diseases within the usculoskeletal/metabolic, hematology, cardiovascular and CNS therapeutic focus areas.”

8. Amazon.com, Inc. (NASDAQ:AMZN)

Louis Bacon’s Stake Value: $19.3 million

Average analyst price target: $176.50

Average analyst price target upside: 21.86%

Amazon.com, Inc. (NASDAQ:AMZN) is a leading tech company that offers services and products focused on AI, cloud computing, e-commerce, online advertising, and digital streaming.

According to Insider Monkey’s database that tracks 910 elite hedge funds, 286 funds held a stake in Amazon.com, Inc.’s stock in Q3, up from 278 in the previous quarter. With 41.353 million shares worth nearly $5.257 billion, Ken Fisher’s Fisher Asset Management was the most prominent stakeholder in the company.

On December 1, Amazon.com, Inc. announced that it is partnering with SpaceX for the deployment of its Project Kuiper internet satellites. The deployment will be carried out over three launches on SpaceX’s Falcon 9 rocket and is expected to be held in mid-2025.

Polen Capital commented on Amazon.com, Inc. in its third quarter 2023 investor letter. Here is what it said:

“Amazon continues to showcase it’s place as one of the most competitively advantaged companies in the world. The company has made significant progress in managing costs and better leveraging existing capacity, driving a strong recovery in its profitability. We think there’s additional room for improvement.

AWS growth seems to be stabilizing even while management continues to work with clients to optimize their infrastructure spend. Roughly 90% of global IT spending remains on premise. We believe this will eventually flip, with most IT spending ultimately moving to the cloud over time. We think AWS will be a significant beneficiary of this transition.

Further, our investment case on company profitability driven by AWS and advertising continues to unfold, delivering nearly $8 billion in free cash flow over the trailing twelve months and a net margin of 5%. We expect both to move higher with the mix shift of more profitable businesses growing fastest continuing to take effect.

At Amazon’s current price, we believe the company is well positioned to deliver a mid-teens or higher total shareholder return for our clients over the next five plus years without a Herculean effort from the business. It simply needs to continue executing on current businesses and growing into the capacity it built during and immediately after the pandemic.”

7. Alight, Inc. (NYSE:ALIT)

Louis Bacon’s Stake Value: $27.1 million

Average analyst price target: $12.00

Average analyst price target upside: 52.09%

Alight, Inc. (NYSE:ALIT) is a cloud-based company that offers integrated digital human capital and business solutions to its 4,300 clients in more than 100 countries.

On November 1, Alight, Inc. posted its Q3 non-GAAP EPS of $0.14, surpassing the estimates by $0.01. While the revenue of $813 million did not manage to beat the estimates, it grew 8.4% YoY.

Over the last three months, 5 Wall Street analysts covered Alight, Inc.’s stock, and all of them maintained a Buy rating on the shares. The average price target of $12 represents an upside of 52.09% as of December 4.

Alight, Inc. was mentioned in Polen Capital’s third-quarter 2023 investor letter. Here is what it said:

“Alight is a leading cloud-based provider of employee engagement tools and solutions for workplace benefits, payroll, administration, and wealth services. The stock negatively reacted to lower-than-expected bookings guidance for its small but growing business-process-as-a-Service (“BPaaS”) segment. Due to the nature of Alight’s business model, the market is putting too much emphasis on BPaaS bookings, in our opinion, which is a flawed metric. We believe business remains healthy, and our long-term expectations for high-single-digit revenue growth with expanding margins remain unchanged.”

6. MetLife, Inc. (NYSE:MET)

Louis Bacon’s Stake Value: $31.41 million

Average analyst price target: $76.78

Average analyst price target upside: 18.95%

MetLife, Inc. (NYSE:MET) is a leading provider of insurance, annuities, and employee benefit programs globally. The company offers its services in around 40 global markets and works with numerous Fortune 500 companies.

On November 15, MetLife, Inc. announced its preferred stock dividends to be payable by December 15 to the shareholders of record on November 30. The dividends include a quarterly dividend of $0.42157266 per share for the floating rate non-cumulative preferred stock, Series A, with a $25 liquidation preference (NYSE:MET PRA). Moreover, it declared a quarterly dividend of $351.5625 per share for the 5.625% non-cumulative preferred stock, Series E, featuring a $25,000 liquidation preference per share, represented by depositary shares, where each share represents a 1/1,000th interest and holders will receive $0.3515625 per depositary share (NYSE:MET PRE).

Finally, MetLife, Inc. declared a quarterly dividend of $296.875 per share for the 4.75% non-cumulative preferred stock, Series F, with a $25,000 liquidation preference per share, also represented by depositary shares, with each share representing a 1/1,000th interest, and holders will receive $0.296875 per depositary share (NYSE: MET PRF).

NVIDIA Corporation, Meta Platforms, Inc., and CRH plc (NYSE:CRH) are some of Louis Bacon’s stock picks with huge upside potential along with MetLife, Inc..

5. Luminar Technologies, Inc. (NASDAQ:LAZR)

Louis Bacon’s Stake Value: $35.667 million

Average analyst price target: $7.57

Average analyst price target upside: 198.03%

Luminar Technologies, Inc. (NASDAQ:LAZR) is a Florida-based company that develops and sells proactive safety and autonomy software solutions, sensors, and consulting services.

On November 10, Luminar Technologies, Inc. announced that its iconic next-generation LiDAR technology will be part of Polestar Automotive Holding UK PLC (NASDAQ:PSNY)’s Polestar 4. The agreement also involves Intel Corporation (NASDAQ:INTC) and is expected to strengthen the existing partnership between the three corporations.

On November 8, Luminar Technologies, Inc. reported its Q3 earnings result with a non-GAAP loss per share of $0.21 and revenue of $16.96 million, which grew 32.7% year-over-year (YoY).

Luminar Technologies, Inc. was covered by 7 Wall Street analysts, and 5 keep a Buy rating on the shares. The average price target of $7.57 has an upside of 198.03%.

4. Teck Resources Limited (NYSE:TECK)

Louis Bacon’s Stake Value: $71.455 million

Average analyst price target: $47.85

Average analyst price target upside: 27.87%

Teck Resources Limited (NYSE:TECK) is a Canadian mining company with diversified operations in mining and mineral development.

On November 20, Teck Resources Limited announced that it has received regulatory approval from the Toronto Stock Exchange to purchase up to 40 million class B Shares between November 22, 2023, and November 21, 2024.

On November 16, Teck Resources Limited announced a quarterly dividend of CAD 0.125, payable by December 29 to the shareholders of record on December 15. The dividend yield of the company was 0.98% as of the December 4 market close.

On November 14, Glencore plc (OTC:GLNCY) confirmed that it would purchase a 77% stake in Teck Resources Limited’s coal business for $6.9 billion in cash. CEO of Teck Resources Limited, Jonathan Price, commented that the company will receive $8.6 billion in cash after the sale, which would go a long way in paying down debt, expanding its base metals production, and returning cash to the shareholders.

3. CRH plc (NYSE:CRH)

Louis Bacon’s Stake Value: $73.99 million

Average analyst price target: $74.56

Average analyst price target upside: 18.43%

CRH plc (NYSE:CRH) is an Ireland-based company that is involved in the production and distribution of construction materials.

On November 22, CRH plc (NYSE:CRH) announced that it reached an agreement with SigmaRoc to divest its lime operations in Europe for a consideration of $1.1 billion. The three phases of the transaction are expected to be completed in 2024.

On November 21, CRH plc (NYSE:CRH) announced that it would acquire a portfolio of cement and ready mixed concrete assets in Texas from Martin Marietta Materials, Inc. (NYSE:MLM). The purchase consideration is $2.1 billion and is expected to be completed in the first half of 2024.

Voss Capital commented on CRH plc (NYSE:CRH) in its third quarter 2023 investor letter. Here is what it said:

“While the market has recently been focused on GPU chips and AI scripts, our attention has been on cement blocks and crushed rocks. We’ve enthusiastically made CRH one of our largest positions ever at cost due to its limited downside. CRH is among the largest aggregates and infrastructure companies in the United States and Europe and has recently relisted to the NYSE from the LSE, which we believe will be a catalyst for the stock to rerate upwards towards peer valuations as its undeniable value hiding in plain sight becomes more widely discussed.

In 1970, Cement Limited and Roadstone Limited, two Irish infrastructure-focused companies, combined to form Cement and Roadstone Holdings, or “CRH.” An investment of $1 million into CRH upon its founding since that fateful merger ~53 years ago would have turned into ~$1.5 billion by mid-year 2023, an annualized total return to investors of 15.0%, a high rate of compounding we think can continue.

Half a century of success at CRH has been driven by disciplined operations and capital allocation that we believe derives from a company culture built around appropriate financial incentives. CRH’s M&A playbook has proven to be successful as an acquisitive company like CRH can’t compound at a rate of 15% over 50 years unless acquisitions and divestitures have been executed at attractive prices. Over the last five years, CRH has spent $10.3 billion on acquisitions while receiving $10.5 billion in proceeds from divestitures across dozens of transactions, with the average acquisition multiple ranging from 7x – 8x EBITDA depending on the year and the average exit multiple clocking in at 11x EBITDA.”

2. Meta Platforms, Inc. (NASDAQ:META)

Louis Bacon’s Stake Value: $271.693 million

Average analyst price target: $387.71

Average analyst price target upside: 21.15%

Meta Platforms, Inc. is a leading tech conglomerate that provides social networking platforms, advertising services, and business insight solutions.

Over the last three months, Meta Platforms, Inc.’s stock was covered by 38 Wall Street analysts, and 37 maintained a Buy rating on the shares. The average price target of $387.71 represents an upside of 21.15% as of the December 4 market close.

On November 22, Tigress Financial increased the price target on Meta Platforms, Inc.’s stock to $435 from $380 and maintained a Strong Buy rating. According to the analyst, the company is well positioned because of its strong presence in the digital advertising sphere, continuous innovation, new products, and AI integration.

Artisan Partners commented on Meta Platforms, Inc. in its third quarter 2023 investor letter. Here is what it said:

“Meta Platforms, Inc. added to its string of gains in Q3. The share price is up about 150% this year. Second quarter results were very good: revenue growth is back to double digits, user metrics are solid and show very good engagement, daily active users grew 7%, and importantly, Facebook app users continue to grow across all geographies. Instagram is growing more strongly, but solid growth in the legacy Facebook business is a positive indicator. Importantly, the company has controlled expenses tightly. Headcount was down 14% year over year. Adjusted EBIT grew 44%, and the margin recovered strongly to 38%, from 29% last year.”

1. NVIDIA Corporation (NASDAQ:NVDA)

Louis Bacon’s Stake Value: $384.312 million

Average analyst price target: $661.00

Average analyst price target upside: 45.24%

NVIDIA Corporation is a California-based tech company that is engaged in the production and distribution of graphics processing units, central processing units, and system-on-a-chip units.

Out of the 910 hedge funds tracked by Insider Monkey, 180 funds had investments in NVIDIA Corporation’s stock in the third quarter, up from 175 in the previous quarter. Rajiv Jain’s GQG Partners was the biggest shareholder of the company, with 14.039 million shares worth over $6.1 billion, representing 14.13% of the fund’s portfolio.

On November 21, NVIDIA Corporation posted Q3 non-GAAP EPS of $4.02, topping the estimates by $0.63. The revenue increased by 205.6% YoY to $18.12 billion, which beat the estimates by $2.01 billion.

NVIDIA Corporation was mentioned in O’keefe Stevens Advisory’s third-quarter 2023 investor letter. Here is what it said:

“This quarter, we actively reduced our position in our favorite company, NVIDIA Corporation. Over the past several years, I have consistently noted the concentration of the top 5 holdings in our portfolio, with NVDA comprising 26% of the last quarter’s 40%. The business, management, and outlook are nothing short of excellent. The business has a dominant market share in a rapidly growing market with competition seemingly years behind, though, fighting hard to gain share. Gross margin is expected to exceed 70% in 2024 and expand in 2025, reflecting the premium customers pay for their advanced technology. Revenue growth of 30%+ on a $50B base and a return on equity over 50%. If this isn’t the best business in the world currently, certainly it is in the top 5.

Jensen is the reason we held onto the stock despite our unease about the valuation. Jensen came to the U.S. from Thailand and was sent to a boarding school in rural Kentucky for troubled youth by his aunt and uncle, who mistook it for a prep school. When buying an ownership stake in the business, we must ask ourselves who we partner with. Are they honest? Capable? Aligned?

Honest: Listening to Jensen (while promotional) is like a breadth of fresh air. He tells you how it is. When the business looked like it was headed for failure in 2009, Jensen reduced his salary to $1….” (Click here to read the full text)

You can also look at the 15 Best High Yield Stocks To Buy and the 25 Most Powerful Countries in the World by Military.

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.